# Cerus Corp: financial statements, quarterly

CERS · Nasdaq · CIK 1020214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cers.md) · [Financials](/companies/cers/financials.md) · [Filings](/companies/cers/filings.md) · [Insiders](/companies/cers/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cers/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [43.2](/filings/0001193125-26-197777.md) | [52.4](/filings/0001193125-26-326295.md) | not reported | not reported | [53.7](/filings/0001193125-26-197777.md) | [57.4](/filings/0001193125-26-326295.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [16.2](/filings/0000950170-24-119535.md) | [17.3 d](/filings/0001193125-26-085678.md) | [19.8](/filings/0000950170-25-061995.md) | [19.0](/filings/0000950170-25-103179.md) | [17.8](/filings/0001193125-25-270039.md) | [19.3 d](/filings/0001193125-26-085678.md) | [20.3](/filings/0001193125-26-197777.md) | [21.2](/filings/0001193125-26-326295.md) | [18.6](/filings/0001193125-25-270039.md) | [20.8 d](/filings/0001193125-26-085678.md) | [19.9](/filings/0001193125-26-197777.md) | [22.9](/filings/0001193125-26-326295.md) |
| Operating income | $m | [(5.2)](/filings/0000950170-24-119535.md) | [1.0 d](/filings/0001193125-26-085678.md) | [(8.0)](/filings/0000950170-25-061995.md) | [(3.8)](/filings/0000950170-25-103179.md) | [(1.0)](/filings/0001193125-25-270039.md) | [(1.4) d](/filings/0001193125-26-085678.md) | [(5.9)](/filings/0001193125-26-197777.md) | [(3.4)](/filings/0001193125-26-326295.md) | [1.2](/filings/0001193125-25-270039.md) | [(0.6) d](/filings/0001193125-26-085678.md) | [(0.4)](/filings/0001193125-26-197777.md) | [(1.9)](/filings/0001193125-26-326295.md) |
| Interest expense | $m | [2.4](/filings/0000950170-23-058320.md) | [2.2 d](/filings/0000950170-24-026195.md) | [2.2](/filings/0000950170-24-052296.md) | [2.3](/filings/0000950170-24-089390.md) | [2.3](/filings/0001193125-25-270039.md) | [2.1 d](/filings/0001193125-26-085678.md) | [2.1](/filings/0001193125-26-197777.md) | [2.2](/filings/0001193125-26-326295.md) | [2.1](/filings/0001193125-25-270039.md) | [2.0 d](/filings/0001193125-26-085678.md) | [1.9](/filings/0001193125-26-197777.md) | [1.7](/filings/0001193125-26-326295.md) |
| Income tax | $m | [0.1](/filings/0000950170-24-119535.md) | [0.1 d](/filings/0001193125-26-085678.md) | [0.1](/filings/0000950170-25-061995.md) | [(0.1)](/filings/0000950170-25-103179.md) | [0.1](/filings/0001193125-25-270039.md) | [0.1 d](/filings/0001193125-26-085678.md) | [0.1](/filings/0001193125-26-197777.md) | [0.1](/filings/0001193125-26-326295.md) | [0.1](/filings/0001193125-25-270039.md) | [0.1 d](/filings/0001193125-26-085678.md) | [0.1](/filings/0001193125-26-197777.md) | [0.1](/filings/0001193125-26-326295.md) |
| Net income | $m | [(7.3)](/filings/0000950170-24-119535.md) | [(1.3) d](/filings/0001193125-26-085678.md) | [(9.7)](/filings/0000950170-25-061995.md) | [(5.8)](/filings/0000950170-25-103179.md) | [(2.9)](/filings/0001193125-25-270039.md) | [(2.5) d](/filings/0001193125-26-085678.md) | [(7.7)](/filings/0001193125-26-197777.md) | [(5.7)](/filings/0001193125-26-326295.md) | [(0.0)](/filings/0001193125-25-270039.md) | [(2.2) d](/filings/0001193125-26-085678.md) | [(1.6)](/filings/0001193125-26-197777.md) | [(2.9)](/filings/0001193125-26-326295.md) |
| Diluted EPS | $ per share | [(0.04)](/filings/0000950170-24-119535.md) | not reported | [(0.05)](/filings/0000950170-25-061995.md) | [(0.03)](/filings/0000950170-25-103179.md) | [(0.02)](/filings/0001193125-25-270039.md) | not reported | [(0.04)](/filings/0001193125-26-197777.md) | [(0.03)](/filings/0001193125-26-326295.md) | [0.00](/filings/0001193125-25-270039.md) | not reported | [(0.01)](/filings/0001193125-26-197777.md) | [(0.01)](/filings/0001193125-26-326295.md) |
| Basic EPS | $ per share | [(0.04)](/filings/0000950170-24-119535.md) | not reported | [(0.05)](/filings/0000950170-25-061995.md) | [(0.03)](/filings/0000950170-25-103179.md) | [(0.02)](/filings/0001193125-25-270039.md) | not reported | [(0.04)](/filings/0001193125-26-197777.md) | [(0.03)](/filings/0001193125-26-326295.md) | [0.00](/filings/0001193125-25-270039.md) | not reported | [(0.01)](/filings/0001193125-26-197777.md) | [(0.01)](/filings/0001193125-26-326295.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [17.4](/filings/0000950170-23-058320.md) | [11.6](/filings/0000950170-25-027906.md) | [20.5](/filings/0000950170-24-052296.md) | [12.4](/filings/0000950170-24-089390.md) | [21.6](/filings/0000950170-24-119535.md) | [20.3](/filings/0001193125-26-085678.md) | [19.5](/filings/0000950170-25-061995.md) | [16.0](/filings/0000950170-25-103179.md) | [15.7](/filings/0001193125-25-270039.md) | [20.0](/filings/0001193125-26-326295.md) | [27.9](/filings/0001193125-26-197777.md) | [18.0](/filings/0001193125-26-326295.md) |
| Current assets | $m | [151](/filings/0000950170-23-058320.md) | [144](/filings/0000950170-25-027906.md) | [138](/filings/0000950170-24-052296.md) | [135](/filings/0000950170-24-089390.md) | [141](/filings/0000950170-24-119535.md) | [152](/filings/0001193125-26-085678.md) | [162](/filings/0000950170-25-061995.md) | [169](/filings/0000950170-25-103179.md) | [167](/filings/0001193125-25-270039.md) | [174](/filings/0001193125-26-326295.md) | [175](/filings/0001193125-26-197777.md) | [157](/filings/0001193125-26-326295.md) |
| Total assets | $m | [206](/filings/0000950170-23-058320.md) | [198](/filings/0000950170-25-027906.md) | [189](/filings/0000950170-24-052296.md) | [185](/filings/0000950170-24-089390.md) | [190](/filings/0000950170-24-119535.md) | [201](/filings/0001193125-26-085678.md) | [207](/filings/0000950170-25-061995.md) | [213](/filings/0000950170-25-103179.md) | [215](/filings/0001193125-25-270039.md) | [222](/filings/0001193125-26-326295.md) | [223](/filings/0001193125-26-197777.md) | [205](/filings/0001193125-26-326295.md) |
| Current liabilities | $m | [80.1](/filings/0000950170-23-058320.md) | [67.5](/filings/0000950170-25-027906.md) | [57.2](/filings/0000950170-24-052296.md) | [53.9](/filings/0000950170-24-089390.md) | [54.3](/filings/0000950170-24-119535.md) | [63.6](/filings/0001193125-26-085678.md) | [69.7](/filings/0000950170-25-061995.md) | [84.4](/filings/0000950170-25-103179.md) | [88.4](/filings/0001193125-25-270039.md) | [101](/filings/0001193125-26-326295.md) | [107](/filings/0001193125-26-197777.md) | [85.8](/filings/0001193125-26-326295.md) |
| Total liabilities | $m | [157](/filings/0000950170-23-058320.md) | [144](/filings/0000950170-25-027906.md) | [139](/filings/0000950170-24-052296.md) | [135](/filings/0000950170-24-089390.md) | [135](/filings/0000950170-24-119535.md) | [144](/filings/0001193125-26-085678.md) | [151](/filings/0000950170-25-061995.md) | [157](/filings/0000950170-25-103179.md) | [153](/filings/0001193125-25-270039.md) | [157](/filings/0001193125-26-326295.md) | [155](/filings/0001193125-26-197777.md) | [134](/filings/0001193125-26-326295.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [48.2](/filings/0000950170-23-058320.md) | [52.7](/filings/0000950170-25-027906.md) | [49.4](/filings/0000950170-24-052296.md) | [49.5](/filings/0000950170-24-089390.md) | [53.5](/filings/0000950170-24-119535.md) | [56.1](/filings/0001193125-26-085678.md) | [55.5](/filings/0000950170-25-061995.md) | [55.4](/filings/0000950170-25-103179.md) | [61.5](/filings/0001193125-25-270039.md) | [64.2](/filings/0001193125-26-326295.md) | [67.6](/filings/0001193125-26-197777.md) | [70.0](/filings/0001193125-26-326295.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.5) d](/filings/0000950170-24-119535.md) | [(15.2) d](/filings/0001193125-26-085678.md) | [2.0](/filings/0000950170-25-061995.md) | [0.4 d](/filings/0000950170-25-103179.md) | [4.1 d](/filings/0001193125-25-270039.md) | [4.9 d](/filings/0001193125-26-085678.md) | [(0.8)](/filings/0001193125-26-197777.md) | [(2.4) d](/filings/0001193125-26-326295.md) | [1.9 d](/filings/0001193125-25-270039.md) | [6.2 d](/filings/0001193125-26-085678.md) | [(3.0)](/filings/0001193125-26-197777.md) | [(2.7) d](/filings/0001193125-26-326295.md) |
| Capital expenditure | $m | [2.6 d](/filings/0000950170-24-119535.md) | [(0.0) d](/filings/0001193125-26-085678.md) | [1.1](/filings/0000950170-25-061995.md) | [0.0 d](/filings/0000950170-25-103179.md) | [0.7 d](/filings/0001193125-25-270039.md) | [1.0 d](/filings/0001193125-26-085678.md) | [0.1](/filings/0001193125-26-197777.md) | [0.5 d](/filings/0001193125-26-326295.md) | [1.8 d](/filings/0001193125-25-270039.md) | [1.3 d](/filings/0001193125-26-085678.md) | [0.2](/filings/0001193125-26-197777.md) | [0.9 d](/filings/0001193125-26-326295.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [177](/filings/0000950170-23-058320.md) | [178](/filings/0000950170-24-052296.md) | [181](/filings/0000950170-24-089390.md) | [181](/filings/0000950170-24-119535.md) | [182](/filings/0000950170-25-061995.md) | [185](/filings/0000950170-25-103179.md) | [185](/filings/0001193125-25-270039.md) | [187](/filings/0001193125-26-197777.md) | [191](/filings/0001193125-26-326295.md) | [192](/filings/0001193125-25-270039.md) | [194](/filings/0001193125-26-197777.md) | [201](/filings/0001193125-26-326295.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 201,524,898 at 2026-07-16, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326295.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.